ArticleDiscover nano2025
Mucoadhesive chitosan-coated boswellic acids nanoparticles as promising gastroprotective nanoagents via modulation of the RAS/ERK signaling pathway.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Thermally Stable Nanoarchitectonics of Bicellar Nanocarriers for Superior Transdermal Delivery ofACS applied materials & interfaces · 2026Article
- Bridging bioactive metabolites ofFrontiers in pharmacology · 2026Review
- Mitochondria-targeted nanotechnology in cardiovascular diseases: a review of recent advances.Regenerative biomaterials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitosan, a natural biological macromolecule, was employed to coat boswellic acids extract nanoparticles (CT/BA NPs) to enhance their gastroprotective potential. This study evaluated the therapeutic effects of CT/BA NPs compared to free boswellic acids (BA) in a murine model of ethanol-induced gastric ulcers. Histological analysis showed that CT/BA NPs preserved gastric gland integrity and minimized inflammatory infiltration, achieving a ~ 97% reduction in ulcer index compared to the ulcer group, whereas BA alone achieved ~ 80% protection. CT/BA NPs treatment markedly modulated key growth factors, with TGF-α and TGF-β1 increased by more than 100% relative to the ulcer group, while VEGF expression was suppressed by ~ 74%, indicating more controlled angiogenesis. In addition, CT/BA NPs significantly reduced RAS and ERK levels (by ~ 1.6- and 1.2-fold, respectively) and lowered TNF-α compared to BA, highlighting their role in regulating the RAS-ERK signaling pathway. The superior mucoadhesive properties of CT/BA NPs (76.4% vs. 15.8% for BA NPs) improved gastric mucosal retention, contributing to localized therapeutic effects. Collectively, these findings demonstrate that CT/BA NPs provide promising gastroprotection by promoting epithelial healing, modulating growth factors and signaling pathways, and mitigating ulcer severity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.